Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Share-based Compensation (2016 - 2025)

Amicus Therapeutics' Share-based Compensation history spans 16 years, with the latest figure at $26.6 million for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation rose 38.37% year-over-year to $26.6 million, compared with a TTM value of $87.4 million through Dec 2025, up 2.95%, and an annual FY2025 reading of $87.4 million, up 2.95% over the prior year.
  • Share-based Compensation for Q4 2025 was $26.6 million at Amicus Therapeutics, up from $18.1 million in the prior quarter.
  • The five-year high for Share-based Compensation was $34.9 million in Q1 2023, with the low at $11.7 million in Q2 2021.
  • Average Share-based Compensation over 5 years is $19.6 million, with a median of $18.1 million recorded in 2023.
  • Biggest YoY gain for Share-based Compensation was 61.59% in 2021; the steepest drop was 25.57% in 2021.
  • Tracing FOLD's Share-based Compensation over 5 years: stood at $13.9 million in 2021, then surged by 33.93% to $18.6 million in 2022, then decreased by 2.85% to $18.1 million in 2023, then rose by 6.2% to $19.2 million in 2024, then soared by 38.37% to $26.6 million in 2025.
  • Per Business Quant, the three most recent readings for FOLD's Share-based Compensation are $26.6 million (Q4 2025), $18.1 million (Q3 2025), and $17.6 million (Q2 2025).